US DRUGMAKERS TAKE TRUMP ADMINISTRATION TO COURT OVER MEDICARE PRICE CONTROLS

October 7, 2026

Major pharmaceutical companies and industry groups have launched a legal challenge against the Trump administration’s effort to impose a “most-favoured-nation” approach to Medicare drug pricing, escalating a battle over how much Americans should pay for prescription medicines.

The industry argues that the administration’s pricing policy could interfere with the established system for determining drug costs and undermine incentives for pharmaceutical research and development. The companies are seeking to block the government from implementing the proposed measures.

The policy is intended to bring US drug prices closer to prices paid in other developed countries, reflecting President Donald Trump’s longstanding argument that American consumers bear an excessive share of global pharmaceutical costs.

The administration has maintained that lowering medicine prices is necessary to reduce the financial burden on patients and taxpayers, particularly through the Medicare programme. Pharmaceutical companies, however, contend that government intervention could reduce revenues available for developing new medicines and could disrupt the US pharmaceutical market.

The lawsuit adds another major legal confrontation to the administration’s efforts to reshape American healthcare pricing. Its outcome could determine how far the federal government can go in linking US drug prices to international benchmarks and could have significant consequences for pharmaceutical companies, Medicare beneficiaries and the wider healthcare industry.